Menu

1 / 35

Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies - ROCHE HOLDING LTD

Top Stories Feed·Vandana Singh·about 12 hours ago
#jMkInAWj
#benzinga#breast#cancer#roche#disease
Reading 0:00
15s threshold

Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies

Vandana SinghBenzinga Staff Writer November 17, 2026, 1:49 PM ETNov 17, 1:49 PM ET2 min read2 min

RHHBYROCHE HOLDING LTD S/ADR by Roche Holding Ltd

$60.52-0.70%

Stock Score Locked: Want to See it?

Benzinga Edge Rankings give you vital metrics on any stock – anytime.

Reveal Full Score Edge Rankings

MomentumN/A

Growth24.67

QualityN/A

ValueN/A

Price Trend

ShortMediumLongOverview On Monday, Roche Holdings AG (OTC:RHHBY) announced that the U.S. Food and Drug Administration approved two treatments across its breast cancer and immunology portfolios, clearing Wilserdly for advanced breast cancer and Gazyva/Gazyvaro for chronic kidney disease.

FDA Approves Oral Breast Cancer Combination Wilserdly

The FDA approved Wilserdly (giredestrant) plus everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

Eligible patients must have an FDA-authorized test…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.